Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
187
resultados
Última actualización
20/05/2024 [06:50:00]
Resumen de: CN118047845A
本发明涉及抗菌肽技术领域，尤其涉及一种原位自组装抗菌肽及其应用。本发明的自组装抗菌肽能够在与微生物菌体接触后发生形变，由纳米颗粒变成纳米纤维状态，显著提高抗菌肽的稳定性。同时，本发明的抗菌肽具备广谱的抗菌活性，在高于MIC浓度下显示出较低的溶血性，具备良好的临床应用价值。
Resumen de: CN118047712A
一类含组蛋白去乙酰化酶抑制剂的类脂类分子及其应用，属于生物医药用材料技术领域。该系列分子将组蛋白去乙酰化酶抑制剂通过可降解的酯键与类脂类分子连接，属于一类新型双功能材料分子。酯基的引入利于材料在体内降解，降低生物毒性；同时，提高组蛋白去乙酰化酶抑制剂的细胞/活体摄取效率，在细胞内部释放组蛋白去乙酰化酶抑制剂，调控染色质三维构造：所释放抑制剂分子剂量较高时可诱发染色质结构变化，进而实现基因治疗及化疗的双模式协同治疗；所释放抑制剂分子剂量较低时可适度降低DNA与组蛋白结合的紧密程度，进而提高基因编辑、碱基编辑等与DNA结构调节相关的RNA/DNA类基因药物在细胞内的工作效率。
Resumen de: CN118045193A
本发明涉及生物医药领域，特别涉及组合物、纳米颗粒、药物及其应用。本发明提供了具备靶向能力的包含CD47siRNA和FTO抑制剂的纳米药物，能够提高RNA甲基化水平，降低肿瘤微环境的乳酸表达，促使M2‑TAMs向M1转化，同时减少肿瘤CD47免疫检查点的表达，使M1‑TAMs具备强大杀伤肿瘤能力，解决了单一检查点抑制剂响应率不高的问题，提高了免疫治疗效果。
Resumen de: CN118045059A
本申请提供了MKP5基因在制备治疗肝纤维化的药物中的应用；其中使用间充质干细胞膜包被载基因纳米粒MSC‑MKP5‑PLGA‑PEI来治疗肝纤维化。本发明提供了肝纤维化的新作用靶点，并通过靶向锚‑间充质干细胞膜包备的纳米递送系统，优先或主动地靶向哺乳动物受损的肝组织并成功递送靶基因MKP5，通过基因表达的转录后调控机制调控相应蛋白的表达，同时保护正常组织免受损害，为肝纤维化的基因治疗打下坚实基础。本发明的此类策略应通过增加治疗剂的治疗指标，同时最小化治疗相关毒性的风险方面来提高治疗效果。
Resumen de: CN118045058A
本发明涉及靶向药物领域，公开了一种用于治疗类风湿关节炎的载药体系及其制备方法和应用。该载药体系包括PLGA、常山酮、生物仿生杂化膜和磷脂化透明质酸，所述生物仿生杂化膜包裹在负载有所述常山酮的所述PLGA的表面，所述磷脂化透明质酸嵌在所述生物仿生杂化膜的表面。本发明提供的用于治疗类风湿关节炎的载药体系不仅具有更高的包封率和载药量，且制备成本更低，还具有优异的生物相容性和生物安全性，具有更优异的抗类风湿关节炎作用。
Resumen de: CN118047844A
本发明涉及抗菌肽技术领域，尤其涉及一种原位转化形成纳米纤维的抗菌肽及其应用。本发明提供的抗菌肽序列为Fmoc‑KLVFFKGFAWNVCVYRNGVRVCHRRAN‑NH2。该抗菌肽在体外自组装形成纳米颗粒，在大肠杆菌存在条件下，形态由纳米颗粒转化为纳米纤维，可以延长滞留时间，提高稳定性。该自组装抗菌肽具有广谱的抗菌活性以及良好的代谢稳定性，可用于细菌感染治疗，具有广泛的应用前景。
Resumen de: CN118045060A
一种由巨噬细胞负载的纳米载药颗粒及其制备方法与应用，属于药物靶向载体技术领域。为解决乐伐替尼等药物对微创消融后HCC的治疗效果受到其在体内非特异性积累和分布限制的问题，本发明制备的负载LEN的MΦs是通过天然M1型MΦs吞噬大肠杆菌膜包被的负载LEN纳米颗粒构建的，其中大肠杆菌膜伪装增强了MΦs的吞噬效率，阻止了MΦs内部LEN的泄漏，并维持LEN@MΦs在免疫抑制肿瘤微环境内的M1型。利用消融诱导的自然炎症梯度引导装载LEN的巨噬细胞靶向肿瘤，使LEN在术后HCC体内递送效率提高10倍，该方法显著抑制肿瘤细胞增殖和新生血管生成，且这种增强的LEN递送刺激了全身免疫反应并诱导了持久的免疫记忆。
Resumen de: CN118045192A
本发明属于医药技术领域，尤其涉及一种无载体共组装纳米粒子及其制备方法和应用，中药单体、p‑gp抑制剂和肝药酶抑制剂、粘附材料通过π‑π堆积、氢键相互作用形成共组装纳米粒。所述的中药单体、双功能抑制剂、粘附分子材料的质量比1:2:5‑1:6:10。本发明的制备方法稳定可靠，制备工艺简单，制得的共组装纳米粒具有超高的载药量，并可以通过增加肠道的粘附、抑制p‑gp的外排和肝药酶的代谢提高抗肿瘤中药分子的口服生物利用度和抗肿瘤作用。
Resumen de: CN118045177A
本发明公开了一种光热剂、合成方法及其纳米颗粒的制备方法与应用。本发明的光热剂的荧光发射波长NIR‑Ⅱ范围，并且其制备的纳米颗粒可以实现NIR‑Ⅱ荧光成像引导的肿瘤光热治疗，NIR‑Ⅱ荧光成像具有成像速度快、灵敏度高等优点。
Resumen de: CN118045179A
本发明适用于生物医学技术领域，提供了一种巨噬细胞功能化载药聚多巴胺纳米粒子的制备及应用，通过将NAR负载在hPDA纳米粒子上，并被巨噬细胞膜包裹，构建了一个仿生纳米平台N/hPDA@M。作为一种具有抗炎特性的光热剂，N/hPDA@M不仅改善了NAR的生物利用度，并且将PTT与免疫治疗相结合，体内外研究表明，该纳米材料不仅抑制生物膜的形成，而且调节巨噬细胞极化，起到免疫调节作用，对感染的皮肤创口表现出良好的治疗效果。
Resumen de: CN118047936A
本发明属于纳米生物技术领域，具体涉及一种有机聚合物PBDTPT及其在制备声敏剂中的应用。本发明通过引入噻二唑并吡啶作为电子受体单元，经Stile聚合反应得到有机聚合物PBDTPT，然后将其与两亲性DSPE‑PEG(2000)经微乳液法制备成纳米粒子。本发明公开的一种高活性氧产率声敏剂，其在聚焦超声处理下能产生单线态氧以及羟基自由基，此外，聚焦超声具有优异的组织穿透能力，因此，声敏剂PBDTPT在超声处理下能有效杀伤肿瘤细胞；由于引入强吸电子受体噻二唑并吡啶，使得声敏剂的能带结构与共轭长度发生改变，其具有较高的活性氧产率以及优异的生物相容性。
Resumen de: CN118048300A
本发明涉及线粒体制剂技术领域，具体涉及一种工程化线粒体及其制备方法和应用。使用脂质体挤出器将修饰有DSPE‑PEG‑RGD的间充质干细胞制备为细胞匀浆，细胞匀浆经过差速离心获得工程化线粒体。工程化线粒体包括细胞膜外壳和包裹在细胞膜外壳内的线粒体，细胞膜外壳上嵌入有DSPE‑PEG‑RGD，含有线粒体膜蛋白及细胞膜蛋白，具有高的线粒体膜电位，在体内具有靶向功能。本技术方案可以解决现有技术中的线粒体治疗的靶向性以及活性不理想的技术问题，可以进一步适用于其他细胞来源的脂质膜包裹的线粒体及不同短肽修饰的脂质膜包裹的线粒体的制备。本法具有成本低、耗时短、操作简单、产量高的特点，采用本方法可获得结构完整、活性高、可抵抗恶劣病理微环境、具有靶向功能的工程化线粒体。
Resumen de: CN118045178A
本发明涉及一种中空二氧化锰包覆负载阿霉素和吲哚菁绿的硫化铜纳米药物：首先合成了搭载硫化铜粒子的二氧化硅纳米颗粒（sSiO2@CuS NPs），然后利用氧化还原法在sSiO2@CuS NPs的外表面包覆上中空MnO2外壳，接着在碱性环境中刻蚀掉二氧化硅纳米球以得到二氧化锰包覆的硫化铜纳米颗粒。利用中空MnO2纳米壳独特的笼状结构封装化疗药物阿霉素和光敏剂吲哚菁绿，大大提高对其负载能力，最后在改性的二氧化锰表面修饰肝癌靶向肽9R‑P肽，得到具有肝癌靶向性的中空二氧化锰包覆的硫化铜纳米药物（CIDMP），实现纳米药物光声成像、化学治疗、光热、光动和化学动力学治疗的组合治疗效果。在荷瘤小鼠实验中，在近红外光照射下CIDMP+NIR组治疗的荷瘤小鼠显示出约96.3%的抑瘤率。
Resumen de: WO2024102972A1
Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.
Resumen de: WO2024099975A1
The invention relates to nanoparticles for Cas protein/gRNA ribonucleoprotein (RNP) complex, siRNA or PMO delivery comprising one or more Cas protein/gRNA RNP complex(es), siRNA(s) or PMO(s) as cargo; and a carrier comprising a sequence-defined T-shape lipo-oligomer comprising a tyrosine tripeptide and either a single artificial amino acid or two hydrophobic artificial amino acids at either side of a central lysine branching point and a hydrophobic tail comprising two fatty acids, wherein the artificial amino acid is an oligo(alkylamino) acid. The invention further relates to therapeutic and non-therapeutic uses thereof and to an in vitro method for transfecting mammalian cells.
Resumen de: WO2024102769A2
The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.
Resumen de: WO2024102768A2
The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody or functional fragment thereof, and a lipid nanoparticle (LNP) encapsulating a therapeutic agent, wherein the targeting moiety is conjugated to the LNP through a linker comprising a thiol moiety and a click product formed via a click reaction between a first click handle and a second click handle.
Resumen de: WO2024103022A1
Disclosed are methods for encapsulating pH sensitive cargos, including oxygen binding proteins, in a polydopamine shell.
Resumen de: WO2024102770A1
The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.
Resumen de: WO2024102798A1
Lipid nanoparticles that can be used as active molecule carriers for ophthalmic, dermatological, and/or cosmetic applications. The nanoparticles have an average particle size of less than 80 nm and a permeation enhancer that provides high therapeutic efficacy when applied via ophthalmic or cutaneous routes. The lipid nanoparticles may comprise solid lipids -at room temperature- such as cocoa butter and glyceryl distearate, liquid lipids such as Linoleoyl Polyoxyl-6 glycerides and/or Oleoyl Polyoxyl-6 glycerides, and non-ionic surfactants such as Polyethylene glycol 660 12-hydroxystearate and Polysorbate 80. The lipid nanoparticles can be loaded with active molecules, such as dexamethasone, triamcinolone, prednisolone, betamethasone, dexamethasone sodium phosphate, curcumin, cisplatin, mesalamine, doxorubicin, indomethacin, celecoxib, N- palmitoyl-ethanolamine, timolol maleate, flurbiprofen, ibuprofen, levofloxacin, tobramycin, among others. Moreover, the procedure for obtaining the lipid nanoparticles is carried out without the use of organic solvents and by applying low energy.
Resumen de: WO2024102746A1
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
Resumen de: WO2024101945A1
The present invention relates to a nanoparticle, a nanoparticle complex comprising anti-5'-tRH-GlyGCC bound thereto, and a pharmaceutical composition for preventing or treating cancer comprising same. The present invention may provide an anti-cancer composition with an excellent effect of inhibiting cancer cell proliferation by utilizing the intracellular delivery capability of a nanoparticle.
Resumen de: WO2024101944A1
The present invention relates to a composition for prevention or treatment of autoimmune neurological disorder, comprising nanoparticles (PLGA-siSTAT3) comprising STAT3-specific siRNA and a biodegradable polymer material, the present invention having confirmed that, in an EAE animal model, which is a multiple sclerosis or encephalomyelitis animal model, PLGA-siSTAT3 reduces a clinical symptom index induced by EAE, and inhibits demyelination of the spinal cord. In addition, the present invention has been confirmed to block a STAT3 signaling pathway associated with EAE and thus reduce demyelination, and inhibit microglial and neuroglial expression. In addition, the present invention has been confirmed to inhibit the inflammatory factors iNOS, IL-1β, IL-6, TNF-α, and inhibit the expression of the inflammation-mediating enzyme COX-2 and the chemokines MIP-1α, RANTES. In addition, the present invention has been confirmed to inhibit the invasion and activity of Th1 and Th17 cells associated with autoimmunity and thus enable reducing autoimmune neurological disorder.
Resumen de: WO2024098894A1
Provided are a tumor-targeted imaging nano assembly, a preparation method therefor, and use thereof. The nano assembly comprises an active targeting unit, an imaging signal unit, and metal ions. The active targeting unit is coordinated with the metal ions. The nano assembly is formed by means of coordination self-assembly of a mixture comprising the active targeting unit, the imaging signal unit, and the metal ions. The problems of low signal strength and lack of tumor microenvironment responsiveness of existing tumor imaging probes are solved, such that deep-tissue tumor imaging, diagnosis and treatment can be achieved.
Nº publicación: WO2024098127A1 16/05/2024
Solicitante:
PEARSON SAUDE ANIMAL S A [BR]
UNIV DE SAO PAULO USP [BR]
PEARSON SAUDE ANIMAL S.A,
UNIVERSIDADE DE S\u00C3O PAULO - USP
Resumen de: WO2024098127A1
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous solubility, is encapsulated in a nanostructured lipid system comprising a solid lipid, a liquid lipid, a surfactant and a co-surfactant. Optionally, the system of the invention can be additionally coated with an antibacterial cationic agent. The nanostructured lipid system according to the invention allows the topical administration of besifloxacin in the eyes and gives the drug a longer retention time on the surface of the eye. Furthermore, the system described herein is designed using industrially applicable methods and remains stable under storage conditions for at least 90 days, so it can be readily reproduced on an industrial scale.
BOPI
Sede Electrónica
